





# Why a OH AMR Partnership? Antimicrobial Resistance: one of the major threats to global health

#### **ECDC 2009**

Extra healthcare costs and productivity losses > €1500M Euro/year

#### **EARS-Net report 2019**

Annually in the EU 33,100 patients die from multidrug resistant bacteria annually



By 2050, 10 million people will die from AMR each year worldwide

## Global burden of bacterial antimicrobial resistance 2022


4.95 million deaths associated with bacterial AMR in 2019

(Lancet, Jan 2022)

Antimicrobials are an essential part of modern medicine Unless addressed, AMR threatens a return to the pre-antibiotic era



## **OH AMR One Health Scope: impact to human health**



## **Towards the One Health AMR Partnership**

- Form: European Co-funded Partnership
- Lead EC: DG RTD People Combatting Diseases
- Lead MS: Sweden Swedish Research Council
- Lead Entity: CSA "DESIGN OH AMR" with support from JPIAMR
- Partnership Partners:
  - Research funding agencies
  - In association with other key actors: ministries, international AMR policy bodies, international AMR funders, international AMR initiatives, stakeholders, other relevant European Partnerships
- Definition: "A joint research and innovation programme agreed between MS research funders with co-funding from the EU."
- Launch: 2025


www.ohamr.eu


• Estimated budget: 330Meur (from which EC contribution 100Meur)



## OH AMR joint research programme 2025-2032 An European Co-Funded Partnership for One Health AMR: A joint research and innovation programme agreed

An European Co-Funded Partnership for One Health AMR: A joint research and innovation programme agreed between MS research funders with co-funding from the EU





### **OH AMR Mission and Objectives - summary**



To boost One Health research and innovation leading to improved surveillance of resistant pathogens, better diagnostics and effective treatment of infections and to prevention measures reducing the use of antimicrobials and spread of AMR

#### G01

Strengthen resilience to the AMR threat in Europe and beyond

#### **GO2**

Enhance evidence-based policy measures and innovative solutions to prevent, detect, control, and treat drug-resistant infections in humans

#### **SO1**

**Enhance global and European synergy**, multi-sectoral collaboration, and alignment of joint strategic OH AMR R&I policies

#### SO<sub>2</sub>

**Boost research & innovation** to enhance knowledge and develop solutions to understand, prevent, and tackle AMR

#### SO3

Enhance **knowledge translation and uptake** of research and innovations into solutions and evidence-based policy

#### 001

Coordination and prioritisation of R&I activities

#### 002

Support capacity building programmes and sharing and (re)use of data

#### 003

Increased joint support of R&I actions to prevent and treat drug resistant infections, improved surveillance, diagnosis and control of the spread of resistant microorganisms

#### 004

Support dissemination and exploration strategies for research-healthcare-patient-policy-industry-community engagement



## **Portfolio of Programmes**

Align national AMR research programmes as well as internationally with WHO and UN agendas on AMR by international cooperation across sectors, mobilise investments, coordination of international funding, reinforcement of research abilities and acceleration of research translation.












## **EUP OH AMR countries membership - expansion**





## How to be engaged?

#### **Autum 2023:**

- Roadmap Consultations
- Funders consultations
- Workshops ...

#### Contact:

ohamr@vr.se

www.ohamr.eu

@OHAMR\_News

https://www.linkedin.com/company/oh-amr-partnership/



# OH AMR